Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus PLUVICTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus PLUVICTO.
INDIUM IN 111 CHLORIDE vs PLUVICTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. After binding, the radioactive isotope lutetium-177 emits beta particles, causing DNA damage and cell death.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is administered intravenously at a dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, in combination with a gonadotropin-releasing hormone (GnRH) analog or after prior unilateral orchiectomy.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Effective half-life of lutetium-177 is approximately 160 hours (6.67 days), reflecting both physical decay (T1/2 6.647 days) and biological clearance. Clinical context: Due to physical decay, therapeutic radioactivity decreases to <1% after about 45 days.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Primarily renal; approximately 60% of administered radioactivity excreted in urine within 24 hours, with gradual elimination thereafter. Biliary/fecal excretion accounts for <15%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical